Providing Experienced Leadership in Drug Development
Flexion's founders, Michael Clayman, MD, and Neil Bodick, MD, PhD, are experienced pharmaceutical drug developers with broad product and regulatory expertise. They created and led Chorus, an autonomous drug development division within Eli Lilly Research Laboratories. During their tenure at Chorus, they managed a steady-state portfolio of ten novel compounds, advancing 19 compounds, both small and large molecules, across six different therapeutic areas. They validated new mechanisms of action in the clinic, provided proof of differentiation from competitors in the market and generated defining clinical data far more efficiently than the industry standard. Flexion's founders also ran the regulatory hurdles to oversee the global submission and approval of seven new molecular entities.
The Flexion team will continue this solid track record of accomplishment in drug development to ensure future success at Flexion.
Achieving Clinical PoC: A Comparison
